ECM
RCUS icon

Everence Capital Management’s Arcus Biosciences RCUS Stock Holding History

Everence Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,060
Closed -$153 – 802
2024
Q2 		$153 Hold
10,060
– – 0.01% 717
2024
Q1 		$190 Hold
10,060
– – 0.01% 722
2023
Q4 		$192K Hold
10,060
– – 0.01% 709
2023
Q3 		$181 Hold
10,060
– – 0.01% 691
2023
Q2 		$207K Hold
10,060
– – 0.02% 638
2023
Q1 		$183 Hold
10,060
– – 0.02% 700
2022
Q4 		$208 Hold
10,060
– – 0.02% 683
2022
Q3 		$263K Hold
10,060
– – 0.02% 555
2022
Q2 		$255K Buy
+10,060
New +$246K 0.02% 566

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Everence Capital Management's RCUS Position: Q3 2024 in Review

Everence Capital Management sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 10,060 shares — an estimated $153 sold.

Everence Capital Management first reported a position in RCUS in Q2 2022 and held it in 9 quarters. The position peaked at $263K in Q3 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Everence Capital Management reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Everence Capital Management sold 10,060 Arcus Biosciences shares in Q3 2024, an estimated $153.
  • Everence Capital Management first reported a position in Arcus Biosciences in Q2 2022 and held it in 9 quarters.
  • Everence Capital Management's Arcus Biosciences position peaked at $263K in Q3 2022.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Everence Capital Management's 13F filing for Q3 2024, filed 21 Oct 2024.